多西紫杉醇联合奥沙利铂治疗中晚期食管癌32例疗效观察  被引量:3

Clinical Observation of Docetaxel Combined with Oxaliplatin in the Treatment of 32 Cases with Advanced Esophageal Cancer

在线阅读下载全文

作  者:栾天燕[1] 尹宝玉[1] 韩强[1] 李京云[1] 

机构地区:[1]保定市肿瘤医院,河北保定100071

出  处:《肿瘤学杂志》2010年第10期802-804,共3页Journal of Chinese Oncology

摘  要:[目的]探讨多西紫杉醇联合奥沙利铂治疗中晚期食管癌的疗效及毒副反应。[方法]32例经病理证实中晚期食管癌患者,多西紫杉醇60~75mg/m2,静脉滴注,d1,70岁以上老年患者35~40mg/m2,静脉滴注,d1、8;奥沙利铂100mg/m2,静脉滴注,d2。21d为1个周期。[结果]32例患者中,CR1例(3.13%),PR12例(37.50%),SD9例(28.13%),PD10例(31.25%),总有效率为40.63%,临床获益率为68.75%。其中初治患者有效率44.44%,复治患者有效率35.71%。主要毒副反应为骨髓抑制和神经感觉异常,非血液学毒性反应较轻,无化疗相关死亡。[结论]多西紫杉醇联合奥沙利铂治疗中晚期食管癌疗效较好,且毒副反应可耐受。[Purpose] To investigate the response and toxicity of docetaxel(TXT) combined with oxali- platin(OXA) in the treatment of advanced esophageal cancer. [Methods] Thirty-two cases with advanced esophageal cancer pathologically proved were enrolled. All patients received docetaxel 60~ 75mg/m2, iv gtt, d1; except patients over 70 years old received docetaxel 35~40mg/m2, iv gtt, d1,8. Oxaliplatin 100mg/m2, iv gtt, d2. Twenty-one days as a cycle. [Results] Of 32 cases, 1 case(3.13%) was CR; 12 (37.50%), PR; 9 (28.13%), SD; and 10 (31.25%), PD. The overall response rate was 40.63%, clinical benefit rate was 68.75%. The response rate in initial treatment group and in recurrence group was 44.44% and 35.71%, respectively. The main toxicity was myelosuppression and nerve toxicity,non-hematic toxicity was mild, no treatment-related death occurred. [Conclusion]Do-cetaxel combined with oxaliplatin is effective and tolerable for advanced esophageal cancer.

关 键 词:食管肿瘤 多西紫杉醇 奥沙利铂 药物疗法 

分 类 号:R735.1[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象